Phase I, Double Blind, Randomized, Placebo-controlled Trial in Healthy Subjects to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing, Followed by an Open Label Repeated Dosing Session in 6 HCV genotype1 Infected Patients.

Trial Profile

Phase I, Double Blind, Randomized, Placebo-controlled Trial in Healthy Subjects to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing, Followed by an Open Label Repeated Dosing Session in 6 HCV genotype1 Infected Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2010

At a glance

  • Drugs Simeprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 15 Jul 2009 Actual initiation date (1 Jan 2007) added as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Actual end date (1 Sep 2007) added as reported by ClinicalTrials.gov.
    • 15 Jul 2009 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT00938899).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top